A new hypertension drug, baxdrostat, has shown potential to provide long-lasting improvements in blood pressure, with some patients maintaining normal readings up to two years after stopping treatment.
The findings have raised hopes among medical researchers studying primary aldosteronism, a condition in which the adrenal glands produce excessive amounts of aldosterone, a hormone that causes the kidneys to retain salt and raises blood pressure.
Professor Morris Brown, a hypertension specialist at Queen Mary University of London, led the study that identified the potential long-term benefits.
He said some patients maintained lower blood pressure long after completing treatment.
“Just under a quarter of the patients came off all treatment and had completely normal blood pressure,” Brown said.
More than one billion people worldwide live with hypertension, including over 12 million in the United Kingdom.
Primary aldosteronism accounts for an estimated five to 10 per cent of hypertension cases. The condition often results from small nodules or benign tumours on the adrenal glands, which trigger excessive aldosterone production.
Doctors commonly treat the condition by surgically removing the affected adrenal gland. However, other factors may contribute to high blood pressure, meaning surgery does not always resolve the condition completely.
Baxdrostat belongs to a class of medicines known as aldosterone synthase inhibitors. It works by reducing the production of aldosterone, thereby limiting the hormone’s effect on blood pressure.
According to the report, the drug received approval in the United States earlier in 2026 for patients whose blood pressure remains uncontrolled despite existing medication. The UK’s National Institute for Health and Care Excellence (NICE) is also assessing it for possible availability through the National Health Service.
The potential long-term effect emerged from a small study involving 14 patients whose blood pressure improved significantly during an initial three-month trial.
The participants continued taking daily baxdrostat tablets for between six and 12 months before stopping treatment. Follow-up checks found that their blood pressure remained lower for up to two years.
Zebra News reports that the findings offer a promising direction for hypertension research. However, the study involved only 14 patients, and larger clinical trials will need to establish how widely the long-term benefits apply.
Full report on New England Journal of Medicine.

